Patent ID: 7919115

Claim:
An ODT consisting essentially of: lamotrigine microcapsules comprising 25 or 200 mg of lamotrigine crystals having an average particle size of about 1-50 μm, coated with a taste-masking layer consisting of ethylcellulose, wherein the average coating weight of said microcapsules is about 15% of the total weight of the microcapsules; and rapidly dispersing granules comprising a granulate of crospovidone and mannitol in a ratio ranging from about 90/10 to about 99/1, wherein the rapidly dispersing granules are about 60% to 70% of the total weight of the ODT; and an additional disintegrant comprising crospovidone; wherein after a single oral administration said ODT provides; a C max in the range of 0.276 to 0.482 ng/mL of lamotrigine, an AUC 0-24 in the range of 4.87 to 8.17 ng·hr/mL of lamotrigine, or both a C max in the range of 0.276 to 0.482 ng/mL of lamotrigine and an AUC 0-24 in the range of 4.87 to 8.17 ng·hr/mL of lamotrigine, if the total amount of lamotrigine in the ODT is 25 mg, or a C max in the range of 2.21 to 3.95 ng/mL of lamotrigine, an AUC 0-24 in the range of 36.0 to 63.6 ng·hr/mL of lamotrigine, or both a C max in the range of 2.21 to 3.95 ng/mL of lamotrigine and an AUC 0-24 in the range of 36.0 to 63.6 ng·hr/mL of lamotrigine, if the total amount of lamotrigine in the ODT is 200 mg.